APAntonia Puchner

Antonia Puchner

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Antonia Puchner has a total of 24 co-authors. Here are the top co-authors by number of shared publications:

  • Silvia Hayer

    Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, 1090, Austria; Division of Rheumatology, University Hospitals Leuven, Leuven, 3000, Belgium

    2 shared publications
  • Stephan Blüml

    Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, 1090 Vienna, Austria

    2 shared publications
  • Birgit Niederreiter

    Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria

    1 shared publication
  • Daniel Aletaha

    Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, 1090 Vienna, Austria

    1 shared publication
  • Elisabeth Simader

    Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Wien, Austria

    1 shared publication
  • Gerhard Krönke

    Department of Internal Medicine 3, Friedrich Alexander University Erlangen-Nuremberg and Universitatsklinikum Erlangen, Erlangen, Germany

    1 shared publication

Latest Publications

  • Bona fide dendritic cells are pivotal precursors for osteoclasts

    by Antonia Puchner, Elisabeth Simader, Victoria Saferding, Melanie Hofmann, Markus Kieler, Julia Brunner, René Pfeifle, Birgit Niederreiter, Gerhard Krönke, Gernot Schabbauer, et al.

    Objectives Osteoclasts (OCs) are myeloid-derived multinucleated cells uniquely able to degrade bone. However, the exact nature of their myeloid precursors is not yet defined. Methods CD11c-diphtheria toxin receptor (CD11cDTR) transgenic mice were treated with diphtheria toxin (DT) or phosphate buffered saline (PBS) during serum transfer arthritis (STA) and human tumour necrosis factor transgenic (hTNFtg) arthritis and scored clinically and histologically. We measured cytokines in synovitis by quantitative polymerase chain reaction (qPCR). We performed ovariectomy in CD11cDTR mice treated with PBS or DT. We analysed CD11cDTR, CD11c-Cre/CX3CR1-STOP-DTR and Zbtb46-DTR-treated mice with DT using histomorphometry and OC of CD11c and Zbtb46 fate reporter mice by fluorescent imaging. We sorted murine and human OC precursors and stimulated them with macrophage colony-stimulating factor (M-CSF) and receptor activator of nuclear factor kappa-B ligand (RANKL) to generate OCs. Results Targeting CD11c+ cells in vivo in models of inflammatory arthritis (STA and hTNFtg) ameliorates arthritis by reducing inflammatory bone destruction and OC generation. Targeting CD11c-expressing cells in unchallenged mice removes all OCs in their long bones. OCs do not seem to be derived from CD11c+ cells expressing CX3CR1+, but from Zbtb46+conventional dendritic cells (cDCs) as all OCs in Zbtb46-Tomato fate reporter mice are Tomato+. In line, administration of DT in Zbtb46-DTR mice depletes all OCs in long bones. Finally, human CD1c-expressing cDCs readily differentiated into bone resorbing OCs. Conclusion Taken together, we identify DCs as important OC precursors in bone homeostasis and inflammation, which might open new avenues for therapeutic interventions in OC-mediated diseases.


  • Open Access

    SAT0072 Mirna-146a is a key player in bone metabolism and osteoporosis

    by V. Saferding, M. Hofmann, J.S. Brunner, M.F. Militaru, A. Puchner, S. Hayer, M. Timmen, R. Stange, J.S. Smolen, S. Blüml

    Background Micro RNAs (miRNAs) play a crucial role in the regulation of bone metabolism. MiR-146a, an important anti-inflammatory miRNA, was found to negatively impact osteogenesis and bone regeneration in vitro, by controlling the differentiation of mesenchymal stem cells. But to date the role of miR-146a in bone remodelling, its influence on bone stability and development of osteoporosis is not known. Objectives The objective of this project is the analysis of the role of miR-146a in bone metabolism. Methods Systemic bone, tibiae and femur, of wt and miR-146a deficient animals was assessed histologically and via µCT analysis, over a period of 3 to 18 months of age. Serum cytokine levels were analysed by Elisa. MRNA expression levels in bone were analysed by qPCR. To induce osteoporosis, ovariectomy (OVX) induced bone loss was performed. Results When we analysed bone volume of long bones histologically as well as with µCT analysis we detected significantly increased trabecular bone mass in miR-146a deficient compared to wt animals, starting at an age of 6 months. However, cortical thickness of systemic bones from miR-146a knock out animals was significantly reduced compared to control mice. Analysis of serum in aged miR-146a deficient animals displayed elevated activity of bone resorbing osteoclasts as amounts of CTX I in miR-146a-/- mice were significantly increased compared to wt animals. Q-PCR analysis of important osteoclast as well as osteoblast marker genes in bones ex vivo displayed elevated expression of signature molecules of both cell types in aged miR-146a deficient mice, suggesting a regulatory role of miR-146a in both osteoclasts as well as osteoblasts. When we induced osteoporosis using the OVX disease model, histological analysis of long bones showed significant trabecular bone loss in ovariectomized wt mice. In contrast, we detected no trabecular bone loss in ovariectomized miR-146a knock out animals, suggesting that loss of miR-146a deficiency protects bone loss induced by oestrogen deficiency. Conclusions MiR-146a seems to control bone turnover and miR-146a deficient mice accrue bone over time. Moreover this miRNA has a negative influence on bone loss occurring during oestrogen loss induced osteoporosis. Therefore miR-146a could be possibly used as a therapeutic target in the treatment of osteoporosis. Disclosure of Interest None declared